Reported 1 day ago
Avidity Biosciences Inc. (NASDAQ: RNA) experienced a 9.02% increase in stock value, closing at $44.74, following a positive report from BofA Securities, which raised its price target from $56 to $65 and issued a 'buy' rating. The investment firm suggested that the current stock price dip could present a buying opportunity. This boost follows Avidity's announcement of a $500 million share issuance aimed at funding late-stage clinical trials and expanding its infrastructure and AOC platform.
Source: YAHOO